Thomas Jefferson University

Jefferson Digital Commons
Department of Medical Oncology Faculty
Papers

Department of Medical Oncology

6-17-2022

Editorial: NK/T-Cell Lymphoma: Biology, Prognostics, Prediction,
and Treatment
Jean El Cheikh
Khodr Terro
Layal Sharrouf
Anjali Mishra
Marcos De Lima

Follow this and additional works at: https://jdc.jefferson.edu/medoncfp
Part of the Oncology Commons

Let us know how access to this document benefits you
This Article is brought to you for free and open access by the Jefferson Digital Commons. The Jefferson Digital
Commons is a service of Thomas Jefferson University's Center for Teaching and Learning (CTL). The Commons is
a showcase for Jefferson books and journals, peer-reviewed scholarly publications, unique historical collections
from the University archives, and teaching tools. The Jefferson Digital Commons allows researchers and interested
readers anywhere in the world to learn about and keep up to date with Jefferson scholarship. This article has been
accepted for inclusion in Department of Medical Oncology Faculty Papers by an authorized administrator of the
Jefferson Digital Commons. For more information, please contact: JeffersonDigitalCommons@jefferson.edu.

EDITORIAL
published: 17 June 2022
doi: 10.3389/fonc.2022.942299

Editorial: NK/T-Cell Lymphoma:
Biology, Prognostics, Prediction,
and Treatment
Jean El Cheikh 1,2*, Khodr Terro 1, Layal Sharrouf 1, Anjali Mishra 3 and Marcos De Lima 4
1

Division of Hematology/Oncology, Department of Internal Medicine, American University of Beirut Medical Center, Beirut,
Lebanon, 2 Bone Marrow Transplantation Program, Department of Internal Medicine, American University of Beirut Medical
Center, Beirut, Lebanon, 3 Division of Hematologic Malignancies and Hematopoietic Stem Cell Transplantation, Department
of Medical Oncology, Sidney Kimmel Cancer Center, Philadephia, PA, United States, 4 Department of Medicine, Division of
Hematology, The Ohio State University, Columbus, OH, United States

Keywords: NK/T-cell lymphoma: biology, prognostics, treatment, diagnosis, prediction

Editorial on the Research Topic
NK/T-Cell Lymphoma: Biology, Prognostics, Prediction, and Treatment

Edited by:
Alessandro Isidori,
AORMN Hospital, Italy
Reviewed by:
Stefano Aldo Pileri,
University of Bologna, Italy
*Correspondence:
Jean El Cheikh
je46@aub.edu.lb
Specialty section:
This article was submitted to
Hematologic Malignancies,
a section of the journal
Frontiers in Oncology
Received: 12 May 2022
Accepted: 23 May 2022
Published: 17 June 2022
Citation:
El Cheikh J, Terro K,
Sharrouf L, Mishra A and
De Lima M (2022) Editorial:
NK/T-Cell Lymphoma:
Biology, Prognostics,
Prediction, and Treatment.
Front. Oncol. 12:942299.
doi: 10.3389/fonc.2022.942299

Frontiers in Oncology | www.frontiersin.org

The Research Topic at hand incorporates a sum of contributions, from our colleagues in South
Korea and China mainly, which shed light on the biology, prognostication, prediction, risk
assessment and treatment of a rare subtype of Epstein-Barr virus (EBV)-related non-Hodgkin
lymphomas, NK/T-cell lymphoma (NKTL).
Although the overall incidence of NKTL is low, it has a higher incidence in certain parts of the
world, especially in Asia and to a lesser extent, in Latin America. It mainly affects the midline area
unfolding as a necrotic granulomatous and potentially extremely disﬁguring lesion. The most
common subtype of NKTL is nasal which appears in the nasal cavity including the nasopharynx,
oropharynx, parts of the aero digestive tract and Waldeyer’s ring. The other subtypes are collectively
referred to as non-nasal NK/T cell lymphoma which involves sites like the skin, testis,
gastrointestinal tract, salivary glands and muscle. NKTL frequently expresses multidrug
resistance-associated P-glycoprotein, which mediates exporting many antitumor agents outside
tumor cells. (Terro et al.)
The prognosis of localized NKTL is signiﬁcantly better than when the disease is relapsed and
refractory (RR). (Gao et al.) suggests a new model of Prognostic Index of Natural Killer Lymphoma
(PINK) named PINK+PD-L1 by including PD-L1 expression as an additional risk factor.
PINK+PD-L1 model effectively identiﬁed RR patients from a population of NKTL patients, and
a 25% lower expression of PD-L1 was shown to be independently associated with RR subtypes of
NKTL patients (P=0.0019). In addition, higher expression of mutations like JAK-STAT, PI3K-AKT,
and NF-kappa B was found in RR patients compared to successfully treated patients. Early
identiﬁcation of RR disease may hopefully lead to early adoption of improved therapies for this
subset of patients thus ultimately improving their prognosis.
The presence of EBV DNA is a well-established prognostic factor in NKTL patients. However,
(Ha et al.) took it a step further by trying to identify which blood compartment in speciﬁc is better at
predicting the clinical outcomes of NKTL. EBV DNA was identiﬁed in whole blood (WB) and in
plasma at both times before and after treatment. Both pre and post-treatment positive plasma EBV
were observed to be signiﬁcantly and independently associated with poor progression free survival
(PFS) and overall survival (OS) rates. On the other hand, there was no signiﬁcant association
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methotrexate. Administering GAD-M regimen along with
radiotherapy lead to compelling 5-year PFS and OS rates of
68.3% and 77.8% respectively. Hence, GAD-M could be
considered a treatment option for such patients
A new salvage regimen is proposed in a case report of
an elderly female patient with treatment resistant NKTL.
(Xia et al.) treated a patient with EBV-associated NKTL
who failed to respond to cyclophosphamide, doxorubicin,
vindesine, and prednisone regimen. However, she achieved a
complete response after three cycles of anti-PD-1 antibody
(tislelizumab) combined with gemcitabine and oxaliplatin
(GemOx) regimen.
We hope the reader will enjoy this Research Topic, and ﬁnd it
to be a useful reference for the multiple ongoing advancements in
prognostication, treatment, risk assessment and management of
NKTL patients.

observed between WB EBV and survival outcomes in NKTL
patients, suggesting that plasma EBV DNA has a superior
prognostic value over WB EBV DNA in NKTL patients.
Patients with hematologic malignancies including NKTL are
at a higher risk of developing secondary hemophagocytic
lymphohistiocytosis (HLH) also known as NK/T cell
lymphoma-associated hemophagocytic syndrome (NK/TLAHS). NK/T-LAHS is a pathologic activation of the immune
system with a rapidly fatal course which further worsens the
prognosis of NKTL. (Li et al.) ﬁnd it essential to develop a way to
predict NK/T-LAHS in NKTL patients to implement a risk
adapted treatment thus improving patients’ prognosis. In their
research article they demonstrated that poor Eastern Cooperative
Oncology Group (ECOG) performance status, B symptoms and
bone marrow invasion were collectively signiﬁcantly associated
with the occurrence of NK/T-LAHS. The authors developed their
ﬁrst risk model called risk index for NKTL (RINK). This was
followed by a second risk model called risk index for NKTLEpstein-Barr virus (RINK-E) which included high viral EBVDNA copies (≥4,450 copies/ml) as an additional risk factor to
RINK. Both nomograms RINK and RINK-E were validated in a
large cohort of NKTL patients and were highly accurate at
predicting NK/T-LAHS.
This Research Topic also includes a retrospective study by
(Liu et al.), which tackled the prognosis, survival and treatment
outcomes in a cohort of 336 advanced stage NKTL patients. This
study has contributed effectively to the limited pool of data
existing on such a rare subtype of NKTL patients. Patients
treated with asparaginase containing chemotherapy showed
better overall response rate (65.2% vs. 47.8%, P = 0.006) and
better complete remission rates (45.5% vs. 23.9%, P < 0.001) than
patients treated without Asparaginase-containing regimens.
Moreover, 5-year PFS and OS rates were improved by
asparaginase containing regimens (17.1% versus 34.2%, P <
0.001) and (27.8% versus 45.3% P < 0.001) respectively.
Addition of gemcitabine to asparaginase-containing regimens
showed even further improvement in OS.
A very promising new chemotherapy regimen for naïve
NKTL patients was studied by (Wang et al.) in a phase II
clinical trial. The authors reported on 36 newly diagnosed
NKTL patients who were treated with a combination regimen
‘GAD-M’, consisting of peg-asparaginase, gemcitabine, and
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